Thema: US69012T3059
OTLK, US69012T3059
loss-4890196_1920.jpg - Foto: THN
Outlook Therapeutics stock in focus as LYTENAVA rollout advances
Outlook Therapeutics stock traded at 0.42 euros on Friday evening. The company is preparing commercial expansion for its ophthalmic LYTENAVA treatment.
ad-hoc-news.de, 30.10.26 20:43 Uhr
OTLK, US69012T3059
Four analysts set USD 5.03 target for Outlook Therapeutics ...
Four analysts set a USD 5.03 target on October 25, 2026. Outlook Therapeutics stock costs EUR 0.47 on October 27, 2026 at 8:46 p.m. CEST.
ad-hoc-news.de, 27.10.26 20:51 Uhr
OTLK, US69012T3059
Four analysts set a USD 5.03 target for Outlook Therapeutics ...
June net loss reached USD 20.32 million. Outlook Therapeutics stock costs EUR 0.47 on October 24, 2026 at 1:04 p.m. CEST.
ad-hoc-news.de, 24.10.26 20:16 Uhr
OTLK, US69012T3059
Outlook Therapeutics expects December 28 results for Outlook ...
Four analysts set a USD 5.03 average target on October 19, 2026. Outlook Therapeutics stock costs EUR 0.48 on October 20, 2026 after hours.
ad-hoc-news.de, 20.10.26 22:07 Uhr
OTLK, US69012T3059
Outlook Therapeutics stock last at USD 0.49 on October 16 ...
Nasdaq compliance ends March 24, 2027. Outlook Therapeutics stock last at USD 0.49 on October 16, 2026, down 2.00 percent versus Nasdaq.
ad-hoc-news.de, 17.10.26 20:15 Uhr
OTLK, US69012T3059
Outlook Therapeutics stock costs EUR 0.44 volume 59.0 percent ...
Trading volume reached 5,318,221 shares on October 15, 2026. Outlook Therapeutics stock cost EUR 0.44 at 10:52 p.m. CEST.
ad-hoc-news.de, 15.10.26 22:54 Uhr
OTLK, US69012T3059
Outlook Therapeutics files CMS code application and Outlook ...
